Header Logo
Last Name

Naveena Basa Janakiram

TitleProf,Asst of Research
InstitutionUniversity of Oklahoma Health Sciences Center
DepartmentMedicine Hematology/Oncology
Address975 NE 10th St
Oklahoma City OK 73104-5419
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Benbrook DM, Janakiram NB, Chandra V, Pathuri G, Madka V, Stratton NC, Masamha CP, Farnsworth CN, Garcia-Contreras L, Hatipoglu MK, Lighfoot S, Rao CV. Development of a dietary formulation of the SHetA2 chemoprevention drug for mice. Invest New Drugs. 2017 Dec 22. PMID: 29273857.
      View in: PubMed
    2. Mohammed A, Janakiram NB, Madka V, Pathuri G, Li Q, Ritchie R, Biddick L, Kutche H, Zhang Y, Singh A, Gali H, Lightfoot S, Steele VE, Suen CS, Rao CV. Lack of chemopreventive effects of P2X7R inhibitors against pancreatic cancer. Oncotarget. 2017 Nov 17; 8(58):97822-97834. PMID: 29228654.
      View in: PubMed
    3. Janakiram NB, Mohammed A, Bryant T, Ritchie R, Stratton N, Jackson L, Lightfoot S, Benbrook DM, Asch AS, Lang ML, Rao CV. Loss of natural killer T cells promotes pancreatic cancer in LSL-KrasG12D/+ mice. Immunology. 2017 09; 152(1):36-51. PMID: 28419443.
      View in: PubMed
    4. Rao C, Mohammed A, Asch A, Janakiram N. Immunoprevention of Pancreatic Cancer. Curr Med Chem. 2017 Feb 23. PMID: 28240168.
      View in: PubMed
    5. Mohammed A, Janakiram NB, Madka V, Li M, Asch AS, Rao CV. Current Challenges and Opportunities for Chemoprevention of Pancreatic Cancer. Curr Med Chem. 2017 Feb 08. PMID: 28183260.
      View in: PubMed
    6. Rao CV, Janakiram NB, Mohammed A. Molecular Pathways: Mucins and Drug Delivery in Cancer. Clin Cancer Res. 2017 Mar 15; 23(6):1373-1378. PMID: 28039261.
      View in: PubMed
    7. Janakiram NB, Mohammed A, Bryant T, Zhang Y, Brewer M, Duff A, Biddick L, Singh A, Lightfoot S, Steele VE, Rao CV. Potentiating NK cell activity by combination of Rosuvastatin and Difluoromethylornithine for effective chemopreventive efficacy against Colon Cancer. Sci Rep. 2016 Nov 14; 6:37046. PMID: 27841323.
      View in: PubMed
    8. Janakiram NB, Mohammed A, Madka V, Kumar G, Rao CV. Prevention and treatment of cancers by immune modulating nutrients. Mol Nutr Food Res. 2016 06; 60(6):1275-94. PMID: 26833775.
      View in: PubMed
    9. Rao CV, Janakiram NB, Madka V, Kumar G, Scott EJ, Pathuri G, Bryant T, Kutche H, Zhang Y, Biddick L, Gali H, Zhao YD, Lightfoot S, Mohammed A. Small-Molecule Inhibition of GCNT3 Disrupts Mucin Biosynthesis and Malignant Cellular Behaviors in Pancreatic Cancer. Cancer Res. 2016 04 01; 76(7):1965-74. PMID: 26880801.
      View in: PubMed
    10. Rao CV, Sanghera S, Zhang Y, Biddick L, Reddy A, Lightfoot S, Janakiram NB, Mohammed A, Dai W, Yamada HY. Systemic Chromosome Instability Resulted in Colonic Transcriptomic Changes in Metabolic, Proliferation, and Stem Cell Regulators in Sgo1-/+ Mice. Cancer Res. 2016 Feb 01; 76(3):630-42. PMID: 26833665; PMCID: PMC4750399 [Available on 02/01/17].
    11. Rao CV, Janakiram NB, Madka V, Devarkonda V, Brewer M, Biddick L, Lightfoot S, Steele VE, Mohammed A. Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma. Oncotarget. 2015 Oct 20; 6(32):33290-305. PMID: 26429877; PMCID: PMC4741766.
    12. Mohammed A, Janakiram NB, Pant S, Rao CV. Molecular Targeted Intervention for Pancreatic Cancer. Cancers (Basel). 2015 Aug 10; 7(3):1499-542. PMID: 26266422; PMCID: PMC4586783.
    13. Mohammed A, Janakiram NB, Madka V, Brewer M, Ritchie RL, Lightfoot S, Kumar G, Sadeghi M, Patlolla JM, Yamada HY, Cruz-Monserrate Z, May R, Houchen CW, Steele VE, Rao CV. Targeting pancreatitis blocks tumor-initiating stem cells and pancreatic cancer progression. Oncotarget. 2015 Jun 20; 6(17):15524-39. PMID: 25906749; PMCID: PMC4558168.
    14. Janakiram NB, Mohammed A, Rao CV. Sea Cucumbers Metabolites as Potent Anti-Cancer Agents. Mar Drugs. 2015 May 12; 13(5):2909-23. PMID: 25984989; PMCID: PMC4446612.
    15. Janakiram NB, Mohammed A, Bryant T, Lightfoot S, Collin PD, Steele VE, Rao CV. Improved innate immune responses by Frondanol A5, a sea cucumber extract, prevent intestinal tumorigenesis. Cancer Prev Res (Phila). 2015 Apr; 8(4):327-37. PMID: 25657017; PMCID: PMC4839268.
    16. Mohammed A, Janakiram NB, Madka V, Ritchie RL, Brewer M, Biddick L, Patlolla JM, Sadeghi M, Lightfoot S, Steele VE, Rao CV. Eflornithine (DFMO) prevents progression of pancreatic cancer by modulating ornithine decarboxylase signaling. Cancer Prev Res (Phila). 2014 Dec; 7(12):1198-209. PMID: 25248858; PMCID: PMC4310684.
    17. Janakiram NB, Mohammed A, Bryant T, Brewer M, Biddick L, Lightfoot S, Lang ML, Rao CV. Adoptive transfer of regulatory T cells promotes intestinal tumorigenesis and is associated with decreased NK cells and IL-22 binding protein. Mol Carcinog. 2015 Oct; 54(10):986-98. PMID: 24797894.
      View in: PubMed
    18. Janakiram NB, Mohammed A, Brewer M, Bryant T, Biddick L, Lightfoot S, Pathuri G, Gali H, Rao CV. Raloxifene and antiestrogenic gonadorelin inhibits intestinal tumorigenesis by modulating immune cells and decreasing stem-like cells. Cancer Prev Res (Phila). 2014 Mar; 7(3):300-9. PMID: 24431404; PMCID: PMC3951612.
    19. Janakiram NB, Rao CV. The role of inflammation in colon cancer. Adv Exp Med Biol. 2014; 816:25-52. PMID: 24818718.
      View in: PubMed
    20. Mohammed A, Janakiram NB, Brewer M, Ritchie RL, Marya A, Lightfoot S, Steele VE, Rao CV. Antidiabetic Drug Metformin Prevents Progression of Pancreatic Cancer by Targeting in Part Cancer Stem Cells and mTOR Signaling. Transl Oncol. 2013 Dec 01; 6(6):649-59. PMID: 24466367; PMCID: PMC3890699.
    21. Janakiram NB, Mohammed A, Zhang Y, Brewer M, Bryant T, Lightfoot S, Steele VE, Rao CV. Chemopreventive efficacy of raloxifene, bexarotene, and their combination on the progression of chemically induced colon adenomas to adenocarcinomas in rats. Cancer Prev Res (Phila). 2013 Dec; 6(12):1251-61. PMID: 24080207; PMCID: PMC4655595.
    22. Janakiram NB, Mohammed A, Ravillah D, Choi CI, Zhang Y, Desai D, Amin S, Rao CV. Chemopreventive effects of PBI-Se, a selenium-containing analog of PBIT, on AOM-induced aberrant crypt foci in F344 rats. Oncol Rep. 2013 Aug; 30(2):952-60. PMID: 23708609.
      View in: PubMed
    23. Mohammed A, Janakiram NB, Brewer M, Vedala K, Steele VE, Rao CV. Multitargeted low-dose GLAD combination chemoprevention: a novel and promising approach to combat colon carcinogenesis. Neoplasia. 2013 May; 15(5):481-90. PMID: 23633920; PMCID: PMC3638351.
    24. Mohammed A, Janakiram NB, Brewer M, Duff A, Lightfoot S, Brush RS, Anderson RE, Rao CV. Endogenous n-3 polyunsaturated fatty acids delay progression of pancreatic ductal adenocarcinoma in Fat-1-p48(Cre/+)-LSL-Kras(G12D/+) mice. Neoplasia. 2012 Dec; 14(12):1249-59. PMID: 23308056; PMCID: PMC3540949.
    25. Janakiram NB, Rao CV. iNOS-selective inhibitors for cancer prevention: promise and progress. Future Med Chem. 2012 Nov; 4(17):2193-204. PMID: 23190107; PMCID: PMC3588580.
    26. Rao CV, Mohammed A, Janakiram NB, Li Q, Ritchie RL, Lightfoot S, Vibhudutta A, Steele VE. Inhibition of pancreatic intraepithelial neoplasia progression to carcinoma by nitric oxide-releasing aspirin in p48(Cre/+)-LSL-Kras(G12D/+) mice. Neoplasia. 2012 Sep; 14(9):778-87. PMID: 23019409; PMCID: PMC3459273.
    27. Mohammed A, Qian L, Janakiram NB, Lightfoot S, Steele VE, Rao CV. Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48Cre/+ LSL-KrasG12D/+ mice. Int J Cancer. 2012 Oct 15; 131(8):1951-62. PMID: 22287227; PMCID: PMC3376252.
    28. Janakiram NB, Mohammed A, Qian L, Choi CI, Steele VE, Rao CV. Chemopreventive effects of RXR-selective rexinoid bexarotene on intestinal neoplasia of Apc(Min/+) mice. Neoplasia. 2012 Feb; 14(2):159-68. PMID: 22431924; PMCID: PMC3306261.
    29. Janakiram NB, Rao CV. Chemoprevention of Colon Cancer by iNOS-Selective Inhibitors. For Immunopathol Dis Therap. 2012 Jan 01; 3(2):155-167. PMID: 23678395.
      View in: PubMed
    30. Janakiram NB, Mohammed A, Rao CV. Role of lipoxins, resolvins, and other bioactive lipids in colon and pancreatic cancer. Cancer Metastasis Rev. 2011 Dec; 30(3-4):507-23. PMID: 22015691.
      View in: PubMed
    31. Mohammed A, Janakiram NB, Li Q, Choi CI, Zhang Y, Steele VE, Rao CV. Chemoprevention of colon and small intestinal tumorigenesis in APC(Min/+) mice by licofelone, a novel dual 5-LOX/COX inhibitor: potential implications for human colon cancer prevention. Cancer Prev Res (Phila). 2011 Dec; 4(12):2015-26. PMID: 21885812; PMCID: PMC3232346.
    32. Suh N, Reddy BS, DeCastro A, Paul S, Lee HJ, Smolarek AK, So JY, Simi B, Wang CX, Janakiram NB, Steele V, Rao CV. Combination of atorvastatin with sulindac or naproxen profoundly inhibits colonic adenocarcinomas by suppressing the p65/ß-catenin/cyclin D1 signaling pathway in rats. Cancer Prev Res (Phila). 2011 Nov; 4(11):1895-902. PMID: 21764859; PMCID: PMC3208056.
    33. Joyner PM, Waters AL, Williams RB, Powell DR, Janakiram NB, Rao CV, Cichewicz RH. Briarane diterpenes diminish COX-2 expression in human colon adenocarcinoma cells. J Nat Prod. 2011 Apr 25; 74(4):857-61. PMID: 21438584.
      View in: PubMed
    34. Mohammed A, Janakiram NB, Li Q, Madka V, Ely M, Lightfoot S, Crawford H, Steele VE, Rao CV. The epidermal growth factor receptor inhibitor gefitinib prevents the progression of pancreatic lesions to carcinoma in a conditional LSL-KrasG12D/+ transgenic mouse model. Cancer Prev Res (Phila). 2010 Nov; 3(11):1417-26. PMID: 21084261; PMCID: PMC3058550.
    35. Janakiram NB, Mohammed A, Zhang Y, Choi CI, Woodward C, Collin P, Steele VE, Rao CV. Chemopreventive effects of Frondanol A5, a Cucumaria frondosa extract, against rat colon carcinogenesis and inhibition of human colon cancer cell growth. Cancer Prev Res (Phila). 2010 Jan; 3(1):82-91. PMID: 20051375.
      View in: PubMed
    36. Janakiram NB, Rao CV. Role of lipoxins and resolvins as anti-inflammatory and proresolving mediators in colon cancer. Curr Mol Med. 2009 Jun; 9(5):565-79. PMID: 19601807.
      View in: PubMed
    37. Janakiram NB, Steele VE, Rao CV. Estrogen receptor-beta as a potential target for colon cancer prevention: chemoprevention of azoxymethane-induced colon carcinogenesis by raloxifene in F344 rats. Cancer Prev Res (Phila). 2009 Jan; 2(1):52-9. PMID: 19139018.
      View in: PubMed
    38. Janakiram NB, Indranie C, Malisetty SV, Jagan P, Steele VE, Rao CV. Chemoprevention of colon carcinogenesis by oleanolic acid and its analog in male F344 rats and modulation of COX-2 and apoptosis in human colon HT-29 cancer cells. Pharm Res. 2008 Sep; 25(9):2151-7. PMID: 18408893.
      View in: PubMed
    39. Janakiram NB, Rao CV. Molecular markers and targets for colorectal cancer prevention. Acta Pharmacol Sin. 2008 Jan; 29(1):1-20. PMID: 18158862.
      View in: PubMed
    40. Janakiram NB, Cooma I, Mohammed A, Steele VE, Rao CV. Beta-ionone inhibits colonic aberrant crypt foci formation in rats, suppresses cell growth, and induces retinoid X receptor-alpha in human colon cancer cells. Mol Cancer Ther. 2008 Jan; 7(1):181-90. PMID: 18202021.
      View in: PubMed
    Janakiram's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    Co-Authors Expand Description
    Similar People Expand Description
    Same Department Expand Description
    Physical Neighbors Expand Description